Archive for the ‘Sinobiomed Inc. SOBM’ Category

Sinobiomed Inc. (SOBM.OB): Chinese Wonder Drug-Maker?

Friday, September 5th, 2008

Sinobiomed (SOBM) is a Chinese developer of genetically engineered recombinant protein drugs and vaccines. The company’s drugs treat diseases and ailments such as malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Sinobiomed currently has 10 products: three on the market, four in clinical trials and three in research and development.

Sinobiomed, based in the bustling metropolis of Shanghai, could be on the forefront of the burgeoning Chinese biotechnology industry. China’s biotech industry is expected to continue its rapid expansion of 20 percent to 30 percent annually to $8.5 billion by 2010, helped by government contributions of $600 million annually. The Chinese pharmaceutical industry is expected to be the world’s 5th largest market by 2010.

Sinobiomed is considered a market leader in the area of recombinant protein drugs and recently acquired a distributor to facilitate a more expeditious sale of some its drugs. The company has one of China’s largest capacities for the manufacturing of recombinant bioproducts at an extremely low cost and its international alliances give the firm global advantages.

Sinobiomed also has a cosmetics and skin care business that is expected to generate sales of $3 million in the next year with profit margins of over 70 percent. The company is in talks with home shopping TV channels in China, India and other emerging markets to feature its skin care products.

The company said in August it received a $500,000 cash injection from Asian investment fund Accelera Ventures. Sinobiomed had total expenses of $1.8 million for the first three months of this year. Shares closed at 43 cents on Friday and have traded between 21 cents and $3.04 in the past 52 weeks.

Let us hear your thoughts below:

HotStix Stock of the Week – Sinobiomed Inc. (SOBM.OB)

Tuesday, August 26th, 2008

Sinobiomed Inc. (SOBM.OB) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Sinobiomed employs a patented, low-cost, high-yield production process to enhance bioactivity and guarantee the highest levels of purity.

Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials, and three in R&D. The company’s products respond to a wide range of diseases and conditions, including hepatitis B&C, surgical bleeding, diabetic ulcers and burns, malaria, cancer, rheumatoid arthritis, acute liver disease, stroke, blood clots and thrombosis, acute pancreatitis, and blood cell regeneration.

Sinobiomed has several competitive advantages in addition to the company’s patented recombinant protein manufacturing process. One advantage is the company’s strong strategic alliances with leading Chinese research hospitals and institutes for collaborative development of patentable techniques and treatments. Another advantage is the company’s distribution network.

Sinobiomed has also established a nationwide sales and marketing network along with international marketing support programs. The company’s sales efforts were enhanced by its purchase in September, 2007 of a 90% interest in the Suzhou Boai Medical Development Company. Suzhou is an established Chinese pharmaceutical distribution company. Sinobiomed expects the acquisition will expand its market reach and accelerate sales.

Let us hear your thoughts below:

Vaccine Trials, Uses, Progress for Sinobiomed, Inc. (SOBM.OB)

Thursday, August 21st, 2008

Sinobiomed’s (OTCBB: SOBM) recombinant Batroxobin (rBAT) is in its Phase IIb trials for 328 patients. Results are expected before year’s end. A company news release says international interest from government and organizations would grow significantly if the product proceeds to Phase III clinical trials.

“[We have] already received indications of interest from global pharmaceutical companies for joint development, marketing and production,” the release states.

Clinical trials for Sinobiomed’s recombinant malaria candidate vaccine are set to begin before the end of the 3rd Quarter. The tests are tentatively planned to take place at Mahidol University in Bangkok, Thailand.

Batroxobin is produced through genetic engineering of the venom, which reduces the risk of biological contaminates associated with natively extracted batroxobin.

Sinobiomed also has majority ownership in a skincare and cosmetics line, through Shanghai Wanxing Bioscience Cosmetics. Sales of more than $3 million over the coming year are expected, with anticipated gross profit margins greater than 70 percent.

Let us hear your thoughts below:

Dutton Associates Featured Company: Sinobiomed Inc. (SOBM.OB)

Wednesday, July 2nd, 2008

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, one awaiting approval, four in clinical trials and three in research and development. The company’s products treat a wide range of diseases and conditions, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.

Sinobiomed explains its technology like this: “The process of discovering a new drug involves determining which proteins cause or contribute to problems in the body because they are lacking, malfunctioning or present in too great numbers and then identifying and engineering a protein or related molecule to correct the problem. Recombinant DNA technology is the process of removing DNA from one organism and placing it into a new organism that reproduces to make proteins of potential therapeutic value. This technology is at the foundation of biotechnology and Sinobiomed.

“Recombinant protein drugs and other bio-products have three main advantages over traditional chemical pharmaceuticals: their safety, low-cost and efficacy. Because recombinant protein drugs and other biopharmaceuticals are made from human components, such as proteins, enzymes and hormones, they have a built in safety factor. Procedures and processes for developing and purifying these recombined proteins are stringently quality controlled and highly effective and result in products with guaranteed purity of 95% or higher. Sinobiomed uses a patented process that is extremely efficient at purifying recombinant proteins at low cost — and in producing recombinant proteins that are highly efficacious.”

Let us hear your thoughts: Sinobiomed Inc. Message Board